Our service solves standard mRNA carriers' issues (inefficient cytoplasmic delivery, poor antigen display, stability) via bio-functional design and EABR technology, engineering non-infectious self-assembling vectors for gene therapy, vaccines, and oncology.
Creative Biolabs specializes in bio-authentic eVLPs that bypass traditional lipid carriers' limits, delivering customized non-replicative vectors for payload protection and targeted cytoplasmic release, ensuring your candidate has optimal stability, higher immunogenicity, and efficacy.
Enveloped Virus-Like Particles (eVLPs) are self-assembled, non-infectious nanoparticles that mimic the structure of natural enveloped viruses, including a host-derived lipid membrane. eVLPs are used extensively in drug delivery and vaccinology due to their unique advantages: superior stability, high immunogenicity, and the capacity for membrane fusion, which ensures highly efficient cytosolic mRNA release.
Creative Biolabs offers a tailored approach to eVLP design, leveraging various viral scaffolds to match the specific needs of your therapeutic application, target tissue, and desired immunogenic response.
Fig.1 VLP can be classified by morphology into spherical or filamentous, by assembly particle structure into eVLP, non-EVLP, or cVLP, and cVLP can be further divided into chemical coupling according to the type of binding.1
| VLP Type | Core Characteristics | Typical Application Scenarios |
|---|---|---|
| LVLP (Lentivirus-Like Particles) | Supports stable delivery; transduces both dividing and non-dividing cells; enables long-term payload expression; non-infectious by design. | Cell therapy research (e.g., T cell engineering, stem cell modification) |
| MLVLP (Murine Leukaemia Virus-Like Particles) | Well-characterized scaffold; robust self-assembly and budding mechanisms; high-yield production; simplifies process optimization and quality control. | Basic research, anti-retroviral vaccine development, and general gene delivery |
| VEEVLP (Venezuelan Equine Encephalitis Virus-Like Particles) | Specialized for vaccines; triggers strong, rapid immune responses (humoral + cellular); enhances antigen-specific immunity. | Infectious disease vaccines, cancer therapeutic vaccines (tumor antigen display) |
| PEG10-VLP | Assembled with non-viral PEG10 protein; low systemic immunogenicity; superior biophysics (good solubility, low aggregation, adjustable size); boosts in vivo stability. | Innovative delivery projects (e.g., low-immunogenicity mRNA delivery, customized tissue penetration) |
Tab.1 Key Features of Diverse Virus-Like Particle (VLP) Types.
We provide a comprehensive and detailed process, ensuring clear milestones and measurable outcomes for every project. This structured approach is suitable for visualization as a client-facing flowchart, making the path to your final eVLP construct transparent.
Use in silico modeling to select optimal viral scaffolds (e.g., Lentivirus, MLV, VEEV), engineer fusion constructs (with patented motifs like EABR), and generate linearized DNA templates encoding eVLP proteins/ligands.
Transfect eVLP constructs into host cells (e.g., mammalian cells), conduct small-scale expression studies, and verify VLP assembly/budding (via electron microscopy) + surface antigen/ligand expression.
Precisely complex/encapsulate mRNA into pre-formed eVLPs, optimize to ensure high encapsulation efficiency and preserve eVLP/mRNA integrity, yielding crude eVLP-mRNA complexes.
Purify eVLPs via ultracentrifugation/chromatography (remove contaminants), characterize particle size, zeta potential, structural integrity, and mRNA load, obtaining high-purity products meeting QC standards.
Run in vitro assays to assess cellular uptake, membrane fusion, and mRNA translation efficiency, generating data verifying superior delivery/expression vs. LNP controls.
The typical timeframe for the initial eVLP construct development, optimization, and initial characterization ranges from 10 to 16 weeks, depending on the complexity of the viral scaffold selected and the degree of custom targeting required.
Custom Targeted Design
Tailor eVLP envelope components (e.g., viral glycoproteins, ligands) to your mRNA payload and target tissue, and optimize core structure for better encapsulation and nuclease protection.
Scalable Production
Offer one-stop service from lab-scale to commercial manufacturing with flexible bioreactors; use microfluidic mixing and high-density culture for consistent yield.
Efficacy Optimization
Optimize cell culture/purification to boost eVLP titer and purity, and fine-tune envelope proteins for serum stability and endosomal escape.
Quality & Compliance
Apply QbD and PAT to monitor key attributes; conduct safety testing and provide FDA/EMA IND/CTA-compliant docs.
Functional Enhancement
Engineer double-functional eVLP systems (e.g., adjuvant display, CPP fusion) and validate via in vitro/in vivo studies.
Low-Immunogenicity
Remove risky viral components for repeated use; use GMP-grade animal-free materials to avoid contaminants.
Rapid Support
Deliver lab-scale prototypes fast with high-throughput screening; offer end-to-end support (process transfer, troubleshooting).
A: eVLPs offer two major advantages: membrane fusion for superior cytoplasmic release, bypassing endosomal degradation, and the ability to display antigens in a highly ordered, high-density manner for exponentially enhanced immunogenicity (crucial for vaccines). They represent the next evolutionary step in non-viral delivery.
A: Absolutely. Our service is custom by definition. We engineer the eVLP surface envelope to incorporate specific targeting ligands (peptides or antibodies) that bind to receptors uniquely expressed on your target cells (e.g., tumor cells or specific immune subsets).
A: Our versatile eVLP platform can successfully encapsulate a wide range of mRNA types, including those encoding therapeutic proteins, vaccine antigens, and gene editing components (e.g., nucleases). We optimize the encapsulation protocol to maintain the integrity of all sizes and structures of mRNA.
A: All eVLPs are guaranteed to be non-replicative and non-pathogenic. Rigorous QC involves dynamic light scattering for size/homogeneity, zeta potential analysis, endotoxin testing, and functional assays to verify purity and in vitro activity. We provide complete documentation for all regulatory submissions.
Creative Biolabs' Custom Enveloped Virus-Like Particle (eVLP) Development Services provide the definitive solution for overcoming current limitations in mRNA delivery and efficacy. By harnessing the bio-authentic power of membrane fusion and high-density antigen display, we ensure your therapeutic or vaccine candidate achieves maximum potency, stability, and clinical relevance. Partner with Creative Biolabs to secure the next generation of your pipeline.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
